Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Invested Capital (2017 - 2025)

Aclaris Therapeutics has reported Invested Capital over the past 9 years, most recently at $103.1 million for Q4 2025.

  • Quarterly results put Invested Capital at $103.1 million for Q4 2025, down 33.73% from a year ago — trailing twelve months through Dec 2025 was $103.1 million (down 33.73% YoY), and the annual figure for FY2025 was $103.1 million, down 33.73%.
  • Invested Capital for Q4 2025 was $103.1 million at Aclaris Therapeutics, down from $120.1 million in the prior quarter.
  • Over the last five years, Invested Capital for ACRS hit a ceiling of $244.5 million in Q2 2021 and a floor of $103.1 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $156.8 million (2023), compared with a mean of $167.3 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 321.61% in 2021 and later plummeted 33.73% in 2025.
  • Aclaris Therapeutics' Invested Capital stood at $197.3 million in 2021, then rose by 0.14% to $197.6 million in 2022, then decreased by 20.46% to $157.2 million in 2023, then decreased by 1.03% to $155.6 million in 2024, then crashed by 33.73% to $103.1 million in 2025.
  • The last three reported values for Invested Capital were $103.1 million (Q4 2025), $120.1 million (Q3 2025), and $131.7 million (Q2 2025) per Business Quant data.